Search Results 391-400 of 18367 for alopecia

1. Study Of SIM0500 Alone In Participants With Relapsed Or Refractory Multiple Myeloma - Mayo Clinic

   Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy. 2 ...

2. Olaparib and Atezolizumab Either Alone or in Combination in Treating Patients With Stage III-IV Triple Negative Breast Cancer - Mayo Clinic

   ... alopecia). Patients must not have had nitrosoureas or mitomycin C for 6 weeks prior to the initiation of study treatment. Radiation: Prior radiation therapy ...

3. Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss - Mayo Clinic

   Residual chronic toxicities of prior therapy ≤ Grade 2 (eg, peripheral neuropathy, residual alopecia) are allowed. Female subjects who are pre-menopausal ...

4. Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer - Mayo Clinic

   ... alopecia) and/or in whom ≥30% of the bone marrow was irradiated. Patient has had major surgery ≤14 days prior to registration or has not recovered from ...

5. Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 - Mayo Clinic

   alopecia. 15. Receiving herbal supplements or medications known to be strong or moderate inhibitors or inducers of the cytochrome P450 (CYP)2C19 and CYP3A4 ...

6. A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors - Mayo Clinic

   Exceptions are alopecia, hypothyroidism, or type 1 diabetes mellitus controlled with medical intervention, and paronychia controlled with local intervention.

7. Hidradenitis suppurativa - Symptoms and causes - Mayo Clinic

   Uso de la espironolactona en dermatología: Acné, hidradenitis supurativa, alopecia femenina e hirsutismo. Actas Dermosifiliogr. 2020; doi: 10.1016/j.ad ...

8. A Study Of Pirtobrutinib And Brexucabtagene Autoleucel In Relapsed Or Refractory Mantle Cell Lymphoma - Mayo Clinic

   In addition, prior treatment-related AEs must have recovered to Grade ≤ 1 with the exception of alopecia and Grade 2 peripheral neuropathy. Targeted agents ...

9. Study of Magrolimab Combination Therapy to Treat Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer - Mayo Clinic

   previously administered agent. - Note: individuals with any grade neuropathy or alopecia are an exception to this criterion and will qualify for the study ...

10. Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome - Mayo Clinic

    Subjects with vitiligo or alopecia;; Subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement;; Subjects with psoriasis ...